TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetes With Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy Combination With Other Oral Anti-diabetic Agents
Brief Summary: The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs


Options:
A: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
B: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Stratified, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Heterozygous Familial Hypercholesterolemia and Carotid Atherosclerosis Using Carotid Ultrasound (CUS)
Brief Summary: The effects of pactimibe versus placebo on the progression of atherosclerosis in the carotid arteries will be assessed using standard ultrasound techniques.


Options:
A: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS
B: Intervention Type: DRUG; Name: Pactimibe sulfate; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 2
D: Arm Label: ABT-335 + Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335, Other: Atorvastatin | Arm Label: Placebo + Atorvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Atorvastatin | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 + Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Atorvastatin | Intervention Type: OTHER; Name: Atorvastatin; Assigned to Arm(s): ABT-335 + Atorvastatin, Placebo + Atorvastatin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.
Brief Summary: The purpose of this study is to test the long-term safety and tolerability of SPD476 in the maintenance of ulcerative colitis remission.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: abatacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: SPD476 (mesalazine); Assigned to Arm(s): N/A
D: Arm Label: rhuMAb Beta7; Type: EXPERIMENTAL; Interventions: Drug: rhuMAb Beta7 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: rhuMAb Beta7; Assigned to Arm(s): rhuMAb Beta7

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.
Brief Summary: The purpose of this study is to test the long-term safety and tolerability of SPD476 in the maintenance of ulcerative colitis remission.


Options:
A: Arm Label: Mesalamine (Asacol) Once-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Once-Daily | Arm Label: Mesalamine (Asacol) Twice-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Twice-Daily | Intervention Type: DRUG; Name: Mesalamine Once-Daily; Assigned to Arm(s): Mesalamine (Asacol) Once-Daily | Intervention Type: DRUG; Name: Mesalamine Twice-Daily; Assigned to Arm(s): Mesalamine (Asacol) Twice-Daily
B: Intervention Type: DRUG; Name: SPD476 (mesalazine); Assigned to Arm(s): N/A
C: Arm Label: Asacol®; Type: EXPERIMENTAL; Interventions: Drug: Asacol® | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Intervention Type: DRUG; Name: Asacol®; Assigned to Arm(s): Asacol® | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine
D: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD


Options:
A: Arm Label: Methylphenidate transdermal system; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate transdermal system
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate HCl | Intervention Type: DRUG; Name: methylphenidate HCl; Assigned to Arm(s): 001
C: Arm Label: 001; Type: N/A; Interventions: Other: Observational treatment compliance survey | Intervention Type: OTHER; Name: Observational treatment compliance survey; Assigned to Arm(s): 001
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
B: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
C: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (tablet), Drug: Placebo (capsule) | Arm Label: LY2216684 (0.1 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.2 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.3 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Intervention Type: DRUG; Name: LY2216684; Assigned to Arm(s): LY2216684 (0.1 mg/kg/day), LY2216684 (0.2 mg/kg/day), LY2216684 (0.3 mg/kg/day) | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo (tablet); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo (capsule); Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.


Options:
A: Arm Label: OROS MPH; Type: EXPERIMENTAL; Interventions: Drug: OROS MPH | Arm Label: atomoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atomoxetine | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: OROS MPH; Assigned to Arm(s): OROS MPH | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): atomoxetine
B: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: Group 1: Guan-Guan+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guanfacine | Arm Label: Group 2: Placebo-Placebo+DMPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (MPH) | Arm Label: Group 3: Guan-Guan+DMPH (Comb); Type: EXPERIMENTAL; Interventions: Drug: Guanfacine, Drug: Methylphenidate (MPH) | Intervention Type: DRUG; Name: Guanfacine; Assigned to Arm(s): Group 1: Guan-Guan+Placebo, Group 3: Guan-Guan+DMPH (Comb) | Intervention Type: DRUG; Name: Methylphenidate (MPH); Assigned to Arm(s): Group 2: Placebo-Placebo+DMPH, Group 3: Guan-Guan+DMPH (Comb)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.


Options:
A: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
C: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: OROS-Methylphenidate and placebo for inattentive type pts; Type: OTHER; Interventions: Drug: OROS-Methylphenidate and placebo for inattentive type pts | Arm Label: OROS-Methylphenidate and placebo for combined type pts; Type: OTHER; Interventions: Drug: OROS-Methylphenidate and placebo for combined type pts | Intervention Type: DRUG; Name: OROS-Methylphenidate and placebo for inattentive type pts; Assigned to Arm(s): OROS-Methylphenidate and placebo for inattentive type pts | Intervention Type: DRUG; Name: OROS-Methylphenidate and placebo for combined type pts; Assigned to Arm(s): OROS-Methylphenidate and placebo for combined type pts

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Brief Summary: This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System, Placebo patch
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1
C: Arm Label: Group 1: Guan-Guan+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guanfacine | Arm Label: Group 2: Placebo-Placebo+DMPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (MPH) | Arm Label: Group 3: Guan-Guan+DMPH (Comb); Type: EXPERIMENTAL; Interventions: Drug: Guanfacine, Drug: Methylphenidate (MPH) | Intervention Type: DRUG; Name: Guanfacine; Assigned to Arm(s): Group 1: Guan-Guan+Placebo, Group 3: Guan-Guan+DMPH (Comb) | Intervention Type: DRUG; Name: Methylphenidate (MPH); Assigned to Arm(s): Group 2: Placebo-Placebo+DMPH, Group 3: Guan-Guan+DMPH (Comb)
D: Arm Label: 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 15 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsules; Assigned to Arm(s): 10 mg, 15 mg, 20 mg, 40 mg, Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
Brief Summary: The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects the participants sleep and how they perceive their quality of life.


Options:
A: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants
Brief Summary: The safety and efficacy of Intermittent Preventive Treatment for malaria and anaemia control in Infants (IPTi) have already been documented in Southern Tanzania, affording an opportunity to gain operational experience in developing a strategy for the longer-term implementation of IPTi. Working in conjunction with national and district-based health authorities, a strategy will be developed to make IPTi available through routine health services and an effectiveness evaluation conducted. This will be based on the comparison of process and outcome indicators in areas with and without IPTi. Information on safety will be consolidated and the effect of IPTi on the rate of development of drug resistance explored. The acceptability and costs of implementing IPTi will be monitored and combined with assessments of effectiveness (in terms of morbidity and mortality) to assess the cost-effectiveness of IPTi.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Intervention Type: DRUG; Name: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo; Assigned to Arm(s): 1, 2, 3
B: N/A
C: Intervention Type: DRUG; Name: Sulfadoxine pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine used for IPTi, Drug: IPTi | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine used for IPTi; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: IPTi; Assigned to Arm(s): 1

Answer: D